PCA 50941

Drug Profile

PCA 50941

Latest Information Update: 23 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alter
  • Class Antihypotensives; Antimigraines; Dihydropyridines; Thiazoles; Vascular disorder therapies
  • Mechanism of Action Calcium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Glaucoma; Hypotension; Nose disorders

Most Recent Events

  • 11 Jun 2001 No-Development-Reported for Glaucoma in Spain (Ophthalmic)
  • 11 Jun 2001 No-Development-Reported for Hypotension in Spain (IV)
  • 11 Jun 2001 No-Development-Reported for Nose disorders in Spain (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top